Dyskinesia induced by gabapentin in idiopathic Parkinson's disease [6]

Movement Disorders

Volumn 22, Issue 2, 2007, Pages 288-289

  Raju, Prasanth M ^a   Walker, Richard W ^a   Lee, Mark A ^a  

^a NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ENTACAPONE; GABAPENTIN;

AGED; ANAMNESIS; BACKACHE; CASE REPORT; CHOREOATHETOSIS; CLINICAL EXAMINATION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LETTER; LOW DRUG DOSE; MALE; NEUROPATHIC PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; SPINE SURGERY; VERTEBRAL CANAL STENOSIS;

AGED; AMINES; ANTIPARKINSON AGENTS; CYCLOHEXANECARBOXYLIC ACIDS; DYSKINESIA, DRUG-INDUCED; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; PARKINSON DISEASE;

EID: 33847728284     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21209     Document Type: Letter

References (11)

1. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998;280:1831-1836.
2. Schatzberg AF, Nemeroff C, editors. Textbook of Psychopharmacology, 2nd ed. Washington, DC: American Psychiatric Press; 1999. p 449.
3. Taylor CP, Gee NS, Su TZ. A summary of mechanistic hypothesis of gabapentin pharmacology. Epilepsy Res 1998;29:233-249.
4. Buetefisch CM, Gutierrez A, Gutmann L. Choreoathetotic movements: a possible side effects of gabapentin. Neurology 1996;46:851-852.
5. Reeves AL, So EL, Sharbrough FW. Movement disorders associated with the use of gabapentin. Epilepsia 1996;37:988-990.
6. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesia in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
7. Klawans HL, Goetz C, Nausieda PA, Weiner WJ. Levodopa-induced dopamine receptor hypersensitivity. Ann Neurol 1997;2:125-129.
8. Agid Y, Bonnet AM, Ruberg M, Javoy-Agid F. Pathophysiology of levodopa induced abnormal involuntary movements: dyskinesia research and treatment. Psychopharmacology 1985;2(Suppl.):145-159.
9. Van Blercom N, Lasa A, Verger K, Masramon X, Sastre V M, Linazasoro G. A double-blind, placebo-controlled, crossover study in patients with complicated Parkinson disease. Clin Neuropharmacol 2004;27:124-128.
10. Olson WL, Gruenthal M, Mueller ME, Olson WH. Gabapentin for parkinsonism: a double-blind, placebo-controlled crossover trial. Am J Med 1997;102:60-66.
11. Norton JW, Quarles E. Gabapentin-related dyskinesia. J Clin Psychopharmacol 2001;21:623-624.